Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Provided By GlobeNewswire
Last update: Aug 18, 2025
August 18, 2025
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial
in Familial Adenomatous Polyposis (FAP)
Read more at globenewswire.com3.64
-0.51 (-12.29%)
Find more stocks in the Stock Screener
BDRX Latest News and Analysis
